부산대학교 도서관

2011; 22: 28-38. 10.1681/ASN.2010090934 105 Iino Y., Hayashi M., Kawamura T., Shiigai T., Tomino Y., Yamada K., Kitajima T., Ideura T., Koyama A., Sugisaki T. Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension - A Report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study. Keywords: chronic kidney disease; aging; dialysis; palliative care; glomerular filtration rate; creatinine; proteinuria; renal replacement therapy; RAAS; SGLT-2; finerenone; senescence EN chronic kidney disease aging dialysis palliative care glomerular filtration rate creatinine proteinuria renal replacement therapy RAAS SGLT-2 finerenone senescence 1724 18 11/17/22 20221101 NES 221101 1. The US national registry of patients with ESKD revealed that median survival after dialysis initiation was 24.9 months for patients 65 to 79 years of age; 15.6 months for patients 80 to 84 years of age; 11.6 months for patients 85 to 89 years of age; and 8.4 months for patients 90 years of age or older [[68]]. In support of the thesis, the "Renal Risk in Derby" study, conducted on 1741 people with a mean age of 72.9 ± 9 years and with an average GFR of 54 ± 12 mL/min/1.73 m SP 2 sp , confirmed that patients with stage IIIa of CKD have a mortality risk lower than CKD stage IIIb and IV and more importantly, these patients had a similar survival rate than the general population [[29]]. [Extracted from the article]